REPLIGEN CORP
RGEN · XNASCIK 730272fmd_0VBS3PAVQ4VE689FHEH3FJKCJ4Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2009 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 105 | 141 | 194 | 270 | 366 | 671 | 802 | 632 | 634 | 738 |
| Cost of revenue | 47 | 67 | 87 | 119 | 157 | 279 | 346 | 354 | 360 | 352 |
| Gross profit | 57 | 74 | 108 | 151 | 210 | 391 | 456 | 278 | 275 | 386 |
| Realized investment gains (losses) | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Research and development | 7 | 9 | 16 | 19 | 20 | 34 | 44 | 43 | 43 | 54 |
| Selling, general and administrative | 31 | 52 | 66 | 96 | 120 | 184 | 216 | 219 | 263 | 291 |
| Operating income | 16 | 14 | 26 | 36 | 70 | 167 | 225 | 48 | (35) | 55 |
| Interest expense | 4 | 6 | 7 | 9 | 11 | 11 | 1 | 3 | 21 | 22 |
| Other non-operating income (expense) | (4) | (7) | (5) | (10) | (11) | (14) | (6) | 9 | 8 | 7 |
| Income before taxes | 12 | 7 | 21 | 26 | 59 | 154 | 219 | 57 | (27) | 62 |
| Income tax expense | 0 | (21) | 5 | 5 | (1) | 25 | 33 | 21 | (2) | 13 |
| Net income from continuing operations | 12 | 28 | 17 | 21 | 60 | 128 | 186 | 36 | (26) | 49 |
| Net income | 12 | 28 | 17 | 21 | 60 | 128 | 186 | 36 | (26) | 49 |